TD Bank continues to recover from a money-laundering scandal tied to its U.S. operations. Criminal networks were allowed to transfer hundreds of millions of dollars through TD Bank accounts in the U.S. over a six-year period.

As part of an October 2024 settlement with the U.S. Department of Justice and other authorities, TD paid a $3.09 billion U.S. fine. The agreement also capped the size of its U.S. retail banking business, which accounts for roughly a quarter of its earnings. It will probably take five years or more for regulators to lift that cap.

In response, TD overhauled its leadership, replaced its CEO and other senior executives, divested select assets, cut costs, and launched a new growth strategy. These moves have helped restore investor confidence—the stock is up more than 88% since the settlement and now trades at all-time highs.

I asked our Successful Investor research department to draw up this Inner Circle Spotlight report on TD Bank. It explains why we still see TD as a solid buy even after its recent gains. We hope you enjoy this Spotlight Report and profit from it.

You Can See Our WSSF Aggressive Growth Portfolio for May 2026 Here.


We designed our TSINetwork Ratings to give you an idea of the investment quality and risk in stocks we recommend, so you can build a portfolio that suits your needs and objectives.



Other rating systems use a mechanical process to make investment decisions.

APA CORP. $38 (www.apacorp.com) is a hold. In addition to its oil and natural gas properties in West Texas and the U.K.’s North Sea, APA owns one-third of a joint venture that produces natural gas in Egypt. The company recently announced a new natural gas discovery in Egypt’s Western Desert, which could produce 26 million cubic feet per day. That’s equal to 3% of APA’s gas output. The stock has seen recent gains from the conflict in Iran, but it could give them back when passage through the Strait of Hormuz returns to normal. APA Corp. is a hold.

IDEXX LABORATORIES INC. $578 (www.idexx.com) is still a hold. The company makes equipment that veterinarians use to detect diseases in animals.

Danaher’s shares fell recently after it announced a sizeable acquisition. However, the company has a good history of successfully integrating new operations. Moreover, the purchase will quickly add to its earnings, spurring the stock higher in the next few years.

DANAHER CORP. $184 is a buy for aggressive investors. The company (New York symbol DHR; Aggressive Growth Portfolio; Manufacturing & Industry sector; Shares outstanding 707.8 million; Market cap: $130.2 billion; Dividend yield: 0.9%; Price-to-sales ratio: 5.6; TSINetwork Rating: Above Average; www.danaher.com) has more than 15 operating companies that fall into three main categories: Diagnostics (41%, 47%) makes analytical equipment and consumable supplies that hospitals and medical labs use to detect and identify diseases; Biotechnology (30% of revenue in the latest quarter, 37% of earnings) makes instruments for the testing of new drugs and vaccines; and Life Sciences (29%, 16%) makes equipment that researchers use to study DNA and RNA, proteins and cells.

BOEING CO. $221 remains a hold. The aircraft maker (New York symbol BA; Conservative Growth Portfolio, Manufacturing sector; Shares outstanding: 785.6 million; Market cap: $173.6 billion; Price-to-sales ratio: 1.7; Dividend suspended in June 2020; TSINetwork Rating: Extra Risk; www.boeing.com) delivered 143 commercial jetliners in the first quarter of 2026, up from 130 a year earlier.

That gain reflects the company’s return to normal production levels after it fixed various quality control problems with its 737 Max planes. As a result, Boeing delivered 114 of those jets in the latest quarter compared to the 105 a year earlier. It has also increased production of its larger 787 Dreamliner plane.